Australia's Firebrick Pharma gains on patent acceptance in the  Philippines

Firebrick Pharma

18/03/2026 02:20

Updates

** Shares of Australia's Firebrick Pharma FRE.AX rise 5.5% to A$0.058, set for their best day since March 4 if trend holds

** Co says its patent, which protects the use of Nasodine nasal spray or any other intranasal povidone-iodine preparations as a method of reducing the viral load of SARS-CoV-2 in the nose, has been approved in the Philippines

** FRE is currently seeking regulatory approval in the Philippines and anticipates approval during 2026

** Shares up 9.4% YTD

(Reporting by Shruti Agarwal in Bengaluru)

((Shruti.Agarwal@thomsonreuters.com))